As a spin-off from the Netherlands Cancer Institute, Sirius Medical has its roots embedded in the surgical clinic for cancer treatment. They recognized the need and opportunity to simplify and improve the localization technology for the surgical removal of breast cancers, ultimately resulting in the proprietary Sirius Pintuition technology, comprised of a detector, probe and magnetic marker seed. This next-generation tumor localization technique provides surgeons with significant benefits over existing methods. Not only a better clinical outcome due to improved accuracy, but also much simpler in practical use because there is no radio-activity involved and it’s time-saving for radiologists. The Sirius Pintuition provides directional and intuitive localization with millimeter accurate real-time distance feedback, allowing surgeons to remove non-palpable tumors with minimal resection margin and optimal clinical result. The system is CE-approved and clinically validated. The Pintuition Probe is reusable, robust and very simple to use.
Allero Therapeutics is a biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Immune mediated disorders refer to a broad range of conditions such as autoimmune and allergic diseases which result from abnormal activity of the body’s immune system upon exposure to innocuous triggers which may lead the immune system to over-react or start attacking the body. Current therapy of immune mediated disorders remains unsatisfactory as they either do not treat the underlying causes and have significant side effects (autoimmune), or efficacy and compliance is poor (allergy). Allero’s vision is to improve the quality of life and survival of these patients and to achieve this, Allero is developing a next generation proprietary immunotherapy approach SOMIT (Specific Oromucosal Immunotherapy). SOMIT combines a tolerance-inducing agent with targeted delivery of specific antigens to the oral mucosa, an immune-priviliged target. The goal is to restore normal immune balance, avoiding global immune suppression, and treating the cause of the disease.
Citryll’s lead drug programme tACPA, targets the formation of neutrophil extracellular traps (NETs), a part of the innate immune system. Inhibition of NET function and or formation inhibits the release of inflammatory proteins, citrullinated autoantigens as well the release of toxic histones and autoimmune complexes. Citryll’s antibody drug candidates, do so by interfering with formation, function and clearance of NETs, downstream of the protein citrullination pathway catalyzed by peptidylarginine deiminase (PAD) enzymes. tACPA binds to N-terminal citrullinated epitopes in histones that are essential for NET formation.
We believe that drugs that block NET based auto-antigen production have the potential to create game changing new treatments to prevent or treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
The financing round will enable Citryll to conclude the pre-clinical studies and start the clinical safety and efficacy testing of tACPA in patients.
Recent Comments